According to WHO, there will be epidemic of diabetes world over and India is going to be 'A diabetes capital of the world' by 2025. With the increasing incidence of diabetes, the associated complications are also bound to increase. Rhinocerebral mucormycosis is one of them.
Introduction
Mucormycosis refers to a rare and severe infection with fungi of the order of mucorales. Rhizopus species is the most common organism. Humans usually are resistant to this disease because infection with mucorales spores is a frequent event. Hosts who are immuno-compromised with poorly controlled diabetes mellitus (especially with ketoacidosis), glucocorticoid use, neutropenia in the setting of hematological malignancy, solid malignancy, iron overload, and burns are high risk candidates. The disease is unrelated to age, sex and race because the underlying conditions are the major predisposing factors.
The disease begins in the nose, extends to the facial sinuses and may quickly spread to orbit and brain, producing life threatening orbito cerebral manifestations. The fungus attaches to the nasal mucosa where massive spore formation occurs; then it directly invades the blood vessels, causes arterial thrombosis and ischemic necrosis of the affected part. Extension of disease into maxillary and ethmoid sinuses can lead to orbital involvement. Intracranial spread can occur through ophthalmic artery, superior orbital fissure or cribriform plate.
Material and methods
Charts of 13 patients with histopathologically confirmed diagnosis of ROCM from Jan. 03 to Dec. 05 were analyzed. Evaluation at presentation included a detailed history, ENT, ophthalmic and neurological examination to assess the extent of disease. Initial investigations included complete blood counts, blood urea, s. creatinine, bl. Glucose, blood gas analysis, urine for ketone bodies, and diagnostic nasal endoscopy with biopsy. Diagnosis was made on histopathological examination and KOH preparation. CT scan of PNS and brain were obtained to assess the extent of disease. Treatment with systemic Amphotericin B was started as soon as the diagnosis of mucor was established. Treatment was also instituted to stabilize the underlying metabolic derangement.
After a test dose of 1 mg Amphotericin B in 100 ml of normal saline, 1 to 1.5 mg/kg/day of Amphotericin B was given over 4-6 hours. The dose was increased slowly, monitoring serum creatinine and was continued till a cumulative dose of 3 to 5 gm was reached.
The methodology for staging the disease and the management protocol was adopted from studies by Nityanandam et al in 2003, as we have found it to be the most suitable form of analysis for these types of patients.
We identified 3 distinct clinical stages based on the signs and symptoms and degree of disease progression 
Treatment Protocol
Three distinct treatment groups were created based on the nature of surgery that the patients underwent.
Group A -Medical treatment with amphotericin B + sinonasal debridement only Group B -Medical treatment with amphotericin B + sinonasal debridement with orbital exenteration and /or palatal excision. Group C -Only medical treatment with amphotericin B
Medical treatment
All patients received intravenous amphotericin B as soon as diagnosis of mucor was established. The cumulative dose ranged from 3-5 gm. In patients with rising S. creatinitne, amphotericin B was withheld, till it came to normal and treatment was started again. Stage 1 and 2 patients also received local Amphotericin B with gauze soaked in the solution of 50 mg of amphotericin B (1 amp) in 100 ml of normal saline 2 .
